Filing Flows › Accendra Health (ACH) › Q3 2026 › vs Q2 2026
Accendra Health (ACH) Q3 2026 vs Q2 2026 (quarter over quarter)
Accendra Health's revenue fell $11.5M (-2%) from $613M in Q2 2026 to $602M in Q3 2026. The biggest changes: Sleep therapy −$4.1M (-3%); Diabetes −$3.2M (-2%); Urology −$2.6M (-8%).
Accendra Health, Q3 2026: revenue $602M (-14% year over year), operating margin 0.2%, net loss $19.7M, operating cash flow −$17.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Diabetes | $196M | $199M | −$3.2M | -2% |
| Sleep therapy | $144M | $149M | −$4.1M | -3% |
| Home respiratory therapy | $88.9M | $91.0M | −$2.0M | -2% |
| Ostomy | $55.2M | $55.7M | −$448K | -0.8% |
| Other | $47.2M | $47.7M | −$494K | -1% |
| Wound care | $41.6M | $40.2M | $1.4M | +4% |
| Urology | $28.7M | $31.3M | −$2.6M | -8% |
| Revenue | $602M | $613M | −$11.5M | -2% |
| Income tax benefit | $18.9M | −$1.4M | $20.3M | — |
| Net loss | $19.7M | $89.1M | −$69.4M | -78% |
| Costs & expenses | $640M | $702M | −$62.0M | -9% |
| Operating costs | $600M | $648M | −$47.9M | -7% |
| Interest & other, net | $39.9M | $52.5M | −$12.6M | -24% |
| Cost of revenue | $340M | $350M | −$9.4M | -3% |
| SG&A | $249M | $244M | $5.9M | +2% |
| Other operating costs | $10.5M | $55.0M | −$44.5M | -81% |
| Operating cash sources | $58.4M | $95.7M | −$37.3M | -39% |
| Depreciation & amortization | $38.9M | $65.7M | −$26.8M | -41% |
| Share-based compensation | $2.1M | $4.0M | −$1.9M | -47% |
| Cash used in operations | $17.4M | $26.0M | −$8.6M | -33% |
| Net loss absorbed | $19.7M | $89.1M | −$69.4M | -78% |
| Working capital & other | $38.7M | $6.6M | $32.1M | +483% |
Questions
How much did Accendra Health's revenue grow quarter over quarter in Q3 2026?
Accendra Health's revenue fell $11.5M (-2%) from $613M in Q2 2026 to $602M in Q3 2026.
What drove Accendra Health's revenue change in Q3 2026?
Sleep therapy −$4.1M (-3%); Diabetes −$3.2M (-2%); Urology −$2.6M (-8%).